Agendia and Paige Announce Landmark Strategic Partnership to Revolutionize Treatment Planning in Breast Cancer
The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology
MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology has been published in the Journal of Molecular Diagnostics.
Agendia: New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment
BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 molecular subtype and clarified the biology of HER2 "equivocal" breast cancer. 46 percent of women under 50 years of age with an intermediate recurrence score identified as MammaPrint Low Risk enabling greater certainty in treatment management approaches